David Millan

David Millan, Ph.D., is Chief Scientific Officer at Auron. Before joining Auron, Dr. Millan was Vice President of Chemistry at Foghorn Therapeutics, where he built and led the company’s chemistry function and protein degrader platform. At Foghorn, Dr. Millan was a member of the scientific leadership team that oversaw the discovery work for two INDs, as well as a robust preclinical portfolio of programs targeting the chromatin regulatory system. Prior to Foghorn, Dr. Millan was Head of Medicinal Chemistry at FORMA Therapeutics, overseeing programs in tumor metabolism, epigenetics, and protein homeostasis. Earlier in his career, he was a project leader at Pfizer, focused on targets in respiratory and pain. Dr. Millan began his career at Vertex Pharmaceuticals, working on structure-based approaches to kinase inhibitors for oncology.
Dr. Millan has led or overseen the advancement of more than ten development candidates, many of those being first-in-class, across oncology and other disease areas. He earned a B.Sc. with Honors (First class) and Ph.D. in Organic Chemistry from Flinders University in Australia. Dr. Millan completed his post-doctoral training at the University of Nottingham.